Systems Biology Ireland

ucd.ie

SBI established in 2009 under the Science Foundation Ireland CSET programme has successfully developed an integrated mathematical modelling and experimental research programme focusing on the design of new therapeutic approaches to cancer, degenerative and inflammatory diseases based on a systems level, mechanistic understanding of cellular signal transduction networks. SBI is one of the few centres in Europe with the necessary in house expertise, technologies and capabilities to apply systems biology approaches to mammalian models. It’s recognition internationally within the field of systems biology led to the Centre’s invited participation in three large European funded consortia initiatives in 2012 namely the ITFoM, CASyM and ISBE, the last of which is included on the ESFRI 2010 Roadmap.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

EMERGING BIOTECHNOLOGY COMPANY BIOCYTOGEN RAISED 142 MILLION DOLLARS (USD) IN SUPPORT OF PROJECT INTEGRUM

Biocytogen | September 25, 2020

news image

In August, Beijing Biocytogen Biotechnology Co., Ltd. ("Biocytogen") announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secure the implementation of Project Integrum.Project Integrum is a humanitarian effort to discover, develop, and bring to market novel therapeutic antibody candidates against al...

Read More

MICREOS HUMAN HEALTH ENROLLES WORLD'S FIRST ENDOLYSIN-DRUG AS A THERAPY FOR ATOPIC DERMATITIS

Micreos | September 22, 2020

news image

Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardl...

Read More

BIOCLEAN INNOVATIONS AND REP-L® ANTIMICROBIALS PARTNERS TO LAUNCH A POWERFUL NON-TOXIC BIO-BASED ANTIMICROBIAL PRODUCT LINE

Bioclean Innovations | October 19, 2020

news image

Bioclean Innovations Inc, a Biotech startup focused on innovative antimicrobial solutions to combat disease outbreaks has partnered with rep-L® Antimicrobials, to launch a powerful but non-toxic bio-based antimicrobial product line. Our rep-L-based disinfectants are designed to create a new methodology for addressing the infection control challenges facing the education and long-term health care sectors today. The SARS-CoV-2 virus responsible for the COVID-19 pandemic is one of an increasing...

Read More

CELL AND GENE THERAPY

CAPSTAN THERAPEUTICS LAUNCHES WITH $165 MILLION TO DELIVER ON THE CLINICAL PROMISE OF PRECISE IN VIVO CELL ENGINEERING

Capstan | September 15, 2022

news image

Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with $165 million in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy, combining the power of cell therapy with the precision of genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan’s foundational precision in vivo e...

Read More
news image

EMERGING BIOTECHNOLOGY COMPANY BIOCYTOGEN RAISED 142 MILLION DOLLARS (USD) IN SUPPORT OF PROJECT INTEGRUM

Biocytogen | September 25, 2020

In August, Beijing Biocytogen Biotechnology Co., Ltd. ("Biocytogen") announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secure the implementation of Project Integrum.Project Integrum is a humanitarian effort to discover, develop, and bring to market novel therapeutic antibody candidates against al...

Read More
news image

MICREOS HUMAN HEALTH ENROLLES WORLD'S FIRST ENDOLYSIN-DRUG AS A THERAPY FOR ATOPIC DERMATITIS

Micreos | September 22, 2020

Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardl...

Read More
news image

BIOCLEAN INNOVATIONS AND REP-L® ANTIMICROBIALS PARTNERS TO LAUNCH A POWERFUL NON-TOXIC BIO-BASED ANTIMICROBIAL PRODUCT LINE

Bioclean Innovations | October 19, 2020

Bioclean Innovations Inc, a Biotech startup focused on innovative antimicrobial solutions to combat disease outbreaks has partnered with rep-L® Antimicrobials, to launch a powerful but non-toxic bio-based antimicrobial product line. Our rep-L-based disinfectants are designed to create a new methodology for addressing the infection control challenges facing the education and long-term health care sectors today. The SARS-CoV-2 virus responsible for the COVID-19 pandemic is one of an increasing...

Read More
news image

CELL AND GENE THERAPY

CAPSTAN THERAPEUTICS LAUNCHES WITH $165 MILLION TO DELIVER ON THE CLINICAL PROMISE OF PRECISE IN VIVO CELL ENGINEERING

Capstan | September 15, 2022

Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with $165 million in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy, combining the power of cell therapy with the precision of genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan’s foundational precision in vivo e...

Read More